Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis

  • Ali Mahmoud Ahmed, Mohamed Fahmy Doheim, Omar Mohamed Mattar, Nourin Ali Sherif, Duy Hieu Truong, Pham T.L. Hoa, Kenji Hirayama, Nguyen Tien Huy
  • Journal of Medical Virology, February 2018, Wiley
  • DOI: 10.1002/jmv.24947

Combination of Daclatasvir, Asunaprevir, and Beclabuvir in treatment of Hepatitis C virus genotype 1

What is it about?

We assessed a combination of three drugs, namely Daclatasvir, asunaprevir, and beclabuvir, in treatment of Hepatitis C virus (HCV) genotype 1, which is the most prevalent HCV type globally and responsible for 60% of infection.

Why is it important?

This analysis showed high response rates in HCV genotype 1-infected patients treated with the combination irrespective of ribavirin use, prior interferon-based therapy, or restriction on non-cirrhotic patients, IL28B genotype, or baseline resistance-associated variants.

Read Publication

The following have contributed to this page: Mr Duy Hieu Truong and Mohamed Fahmy Doheim